Academic Rank:
Clinical Associate Professor, UBC
Medical Microbiologist and Infectious Diseases Specialist, Royal Jubilee Hospital
Affiliation(s):
Short Bio:

Dr. Galbraith graduated from the University of Alberta medical school in 1983 and subsequently completed residency training in Family Medicine, Internal Medicine, Infectious Diseases and Medical Microbiology. In 1991 he joined the medical staff of the Royal Alexandra Hospital in Edmonton and served as Head of Microbiology and Chief of Infectious Diseases. He joined the medical staff of Dynacare Kasper Medical Laboratories in 1996 and in 2000 was appointed their Medical Director. He served in that capacity until October 2005 when he relocated to beautiful Victoria.

He currently serves as a medical microbiologist with the Vancouver Island Health Authority with particular interest in laboratory quality promotion, epidemiology of blood stream infections, antimicrobial stewardship and the influence of nutrition on immune function.

Academic background

  • MD University of Alberta. 1983
  • BMSc, University of Alberta. 1981

 

Professional Qualifications

  • Specialist Certificate in Medical Microbiology.  1991
  • Certificate of Special Competence in Infectious Diseases.  1991
  • Specialist Certificate in Internal Medicine.  1989
  • ABIM.  Diplomate, American Board of Internal Medicine. 1988
  • ATLS.  Advanced Trauma Life Support. 1987
  • CCFP.  Certification in Family Medicine.  1985
  • LMCC.  Licentiate Medical Council of Canada.  1984
  • ACLS.  Advanced Cardiac Life Support.  1983
  • FRCP( C ).  Fellow, Royal College of Physicians & Surgeons.

 

Publications

  • Laupland KB, Lyytikainen O, Sogaard M, Kennedy KJ, Knudsen JD, Ostergaard C, Galbraith JC, Vlaiquette L, Jacobsson G, Collignon P, Schonheyder HC. The changing epidemiology of Staphylococcus aureus bloodstream infections: a multinational population-based surveillance study. Clinical Microbiology and Infection 2013; 19: 465-471.
  • Laupland KB, Kibsey PC, Gregson DB, Galbraith JC. Population-based. Laboratory Assessment of the Burden of Community-onset Bloodstream Infection in Victoria, Canada. Epidemiology and Infection 2013: 141(1):174-180.
  • Laupland KB, Kibsey PC, Galbraith JC. Community-onset bloodstream infection during the “after hours” is not associated with an increased risk for death. Canadian Journal of Infectious Diseases and Medical Microbiology 2012; 23(4):170-172.
  • Laupland KB, Schonheyder HC, Ostergaard C, Knudsen JD, Valiquette L, Galbraith J, Kennedy KJ, Gradel KO; International Bacteremia Surveillance Collaborative. Epidemiology of Haemophilus influenza bacteremia: a multi-national population-based assessment. Journal of Infection 2011; 62(2):142-148.
  • Laupland KB, Schonheyder HC, Kennedy KJ, Lyytikainen O, Valiquette L, Galbraith J, Collignon P; International Bacteremia Surveillance Collaborative.
    Salmonella enteric bacteraemia: a multi-national population-based cohort study. BMC Infectious Diseases 2010; 10:95. BMC Infectious Diseases 2010; 10:95.
  • Laupland KB, Schonheyder HC, Kennedy KJ, Lyytikainen O, Valiquette L, Galbraith J, Collignon P, Church DL, Gregson DB, Kibsey P. Rationale for and protocol of a multi-national population-based bacteremia surveillance collaborative. BMC Research Notes 2009; 2:146.
  • Houston S, Rowe BH, Mashinter L, Preiksaitis J, Joffe M, Mackey D, Galbraith J, Wiebe N. Sentinel Surveillance of HIV and Hepatitis C Virus in Two Urban Emergency Departments. Canadian Journal of Emergency Medicine 2004; 6(2): 89-96.
  • Hall WC, Jolly DT, Hrazdil J, Galbraith JC, Greacen M, Clanachan AS. The EmulSiv filter removes microbial contamination from propofol but is not a substitute for aseptic technique. Can J Anaesth. 2003 Jun-Jul;50(6):541-6.
  • Wachowski I, Jolly DT, Hrazdil J, Galbraith JC, Greacen M, Clanachan AS. The growth of microorganisms in propofol and mixtures of propofol and lidocaine. Anesth Analg. 1999 Jan;88(1):209-12.
  • Crowther J, Hrazdil J, Jolly DT, Galbraith JC, Greacen M, Grace M. Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesth Analg. 1996 Mar;82(3):475-8.
Primary Research Area
Infectious Diseases and Immunopathology
Secondary Research Area
Endocrinology, Metabolism & Nutrition

Research Interest

Lab quality promotion, antimicrobial stewardship, disease prevention and nutrition